EUVIMEDEUVIMED entdecken
Crossref

Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy

Jianwu Tian, Bowen Li, Fu Zhang, Zhuo Yao, Wentao Song, Yufu Tang, Yuan Ping, Bin Liu iD

Angewandte Chemie International Edition · 13.11.2023 · 62 (46)

DOI: 10.1002/anie.202307288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 09.10.2023. Verfasst von Jianwu Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, National University of Singapore, 5 A Engineering Drive 1, Singapore, 117411, Singapore. Hauptthemen laut MEDLINE: Photochemotherapy, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 154-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National University of Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phototoxicity of photosensitizers (PSs) pre and post photodynamic therapy (PDT), and the hypoxic tumor microenvironment are two major problems limiting the application of PDT. While activatable PSs can successfully address the PS phototoxicity pre PDT, and type I PS can generate reactive oxygen species (ROS) effectively in hypoxic environment, very limited approaches are available for addressing the phototoxicity post PDT. There is virtually no solution available to address all these issues using a single design. Herein, we propose a proof‐of‐concept on‐demand switchable photosensitizer with quenched photosensitization pre and post PDT, which could be activated only in tumor hypoxic environment. Particularly, a hypoxia‐normoxia cycling responsive type I PS TPFN‐AzoCF 3 was designed to demonstrate the concept, which was further formulated into TPFN‐AzoCF 3 nanoparticles (NPs) using DSPE‐PEG‐2000 as the encapsulation matrix. The NPs could be activated only in hypoxic tumors to generate type I ROS during PDT treatment, but remain non‐toxic in normal tissues, pre or after PDT, thus minimizing side effects and improving the therapeutic effect. With promising results in in vitro and in vivo tumor treatment, this presented strategy will pave the way for the design of more on‐demand switchable photosensitizers with minimized side effects in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyNeoplasmsNanoparticlesHumansPhotosensitizing AgentsReactive Oxygen SpeciesHypoxiaCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

HypoxiaOn-Demand Switchable PhotosensitizerPhotodynamic TherapyReversibleType I Photosensitizer

Substanzen

Photosensitizing AgentsReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, National University of Singapore, 5 A Engineering Drive 1, Singapore, 117411, Singapore.
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.

ORCID-Profile: Bin Liu

Förderung

  • National University of Singapore

Zitieren

APA

Tian, J., Li, B., Zhang, F., Yao, Z., Song, W., Tang, Y., Ping, Y., & Liu, B. (2023). Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy. Angewandte Chemie International Edition, 62(46). https://doi.org/10.1002/anie.202307288

Vancouver

Tian J, Li B, Zhang F, Yao Z, Song W, Tang Y, et al. Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy. Angewandte Chemie International Edition. 2023;62(46). doi:10.1002/anie.202307288

BibTeX
@article{Tian2023,
  author = {Tian, Jianwu and Li, Bowen and Zhang, Fu and Yao, Zhuo and Song, Wentao and Tang, Yufu and Ping, Yuan and Liu, Bin},
  title = {Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy},
  journal = {Angewandte Chemie International Edition},
  year = {2023},
  volume = {62},
  number = {46},
  doi = {10.1002/anie.202307288}
}
Kostenlos starten →